Mirati Therapeutics

174 articles with Mirati Therapeutics

• Mirati Therapeutics To Present At The 39th Annual J.P. Morgan Healthcare Conference

  1/4/2021

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11 th at 12:40 p.m. PST / 3:40 p.m. EST . Charles M. Baum , M.D., Ph.D., Mirati's President and Chief Executive Officer will present at the con

• Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference

  11/23/2020

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1st at 8:20 a.m. PT/11:20 a.m. ET. Dan Faga, Executive Vice President and Chief Operating Officer, will represent Mirati at the event.

• Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference

  11/5/2020

  Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Thursday, November 12, 2020 at 9:30 a.m. PT/12:30 p.m. ET.

• Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights

  11/4/2020

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights.

• Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares - Oct 30, 2020

  10/30/2020

  Mirati Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering price of $202.00 per share, which consists of 4,585,706 shares sold by Mirati and 400,000 shares sold by a selling stockholder.

• Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock - Oct 28, 2020

  10/28/2020

  Mirati Therapeutics, Inc. announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of $202.00 per share, which consists of 3,960,397 shares to be sold by Mirati and 375,000 shares to be sold by a selling stockholder.

• Mirati Therapeutics Announces Proposed Public Offering of Common Stock - Oct 26, 2020

  10/26/2020

  Mirati Therapeutics, Inc. announced that it intends to offer and sell in an underwritten public offering $700.0 million of shares of its common stock and a selling stockholder intends to offer 375,000 shares in the offering.

• Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data

  10/25/2020

  45% confirmed ORR and 96% DCR across Phase 1/1b and Phase 2 monotherapy cohorts in patients with advanced NSCLC

• Mirati Therapeutics To Present Data During The 2020 EORTC-NCI-AACR International Virtual Conference On Molecular Targets And Therapeutics (ENA)

  10/15/2020

  - Updated adagrasib (MRTX849) clinical data in non-small cell lung cancer (NSCLC) patients will be featured in a plenary session at ENA - Updated adagrasib clinical data in colorectal cancer (CRC) and other KRAS G12C positive solid tumors outside of NSCLC will be presented in a second session at ENA - Mirati to host virtual investor event on October 25th to discuss adagrasib clinical data presented at ENA and provide an update on MRTX1133, the Company's KRAS G12D selective in

• 

  Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients

  9/21/2020

  San Diego-based Mirati Therapeutics, a clinical-stage biotechnology company, is currently developing sitravatinib to address unmet medical needs in cancer care.

• Mirati Therapeutics Presents Phase 2 Data On Sitravatinib In Combination With Nivolumab In Urothelial Cancer At ESMO Virtual Congress

  9/18/2020

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced updated clinical results from its Phase 2 study evaluating sitravatinib in combination with nivolumab (OPDIVO®) in patients with advanced or metastatic urothelial carcinoma.

• Boehringer Ingelheim And Mirati Therapeutics Announce Clinical Collaboration To Study BI 1701963, A SOS1::pan-KRAS Inhibitor In Combination With MRTX849, A KRAS G12C Selective Inhibitor

  9/17/2020

  Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation.

• Mirati Therapeutics To Participate In Citi's 15th Annual Biopharma Virtual Conference

  9/3/2020

   Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will participate in a fireside chat at the Citi 15 th Annual Biopharma Virtual Conference on Thursday, September 10, 2020 at 11:40 a.m. ET / 8:40 a.m. PT . Dan Faga, Executive Vice President and Chief Operating Officer, wil

• Mirati Therapeutics Reports Second Quarter 2020 Financial Results And Recent Business Highlights

  8/6/2020

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the second quarter ended June 30, 2020.

• ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

  8/5/2020

  ORIC licenses exclusive worldwide development and commercialization rights to a potential best-in-class PRC2 inhibitor

• Mirati Therapeutics to Present at 41st Annual Goldman Sachs Global Healthcare Conference

  6/5/2020

   Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41 st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 . Charles M. Baum , M.D., Ph.D., President and Chief Executive Officer at Mirati will represent the Company during the fireside

• Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer

  5/18/2020

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque, M.D. has been named Chief Medical Officer effective May 18, 2020

• Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II

  5/15/2020

   Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's pipeline of novel therapeutics in three presentations at the American Association for Cancer Research Virtual Annual Meeting II, taking place June 22-24, 2020 . The data to be presented will

• Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates

  5/7/2020

  Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results and a corporate update for the first quarter ended March 31, 2020.

• Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates

  2/25/2020

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year-ended December 31, 2019.